Exosomes released by imatinib‑resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib‑sensitive cells in the presence of imatinib
Chronic myeloid leukemia (CML) is a malignant hematopoietic disorder distinguished by the presence of a BCR‑ABL1 fused oncogene with constitutive kinase activity. Targeted CML therapy by specific tyrosine kinase inhibitors (TKIs) leads to a marked improvement in the survival of the patients and their quality of life. However, the development of resistance to TKIs remains a critical issue for a subset of patients. The most common cause of resistance are numerous point mutations in the BCR‑ABL1 gene, followed by less common mutations and multiple mutation-independent mechanisms. Recently, exosomes, which are extracellular vesicles excreted from normal and tumor cells, have been associated with drug resistance and cancer progression. The aim of the present study was to characterize the exosomes released by imatinib‑resistant K562 (K562IR) cells. The K562IR‑derived exosomes were internalized by imatinib‑sensitive K562 cells, which thereby increased their survival in the presence of 2 µM imatinib. The exosomal cargo was subsequently analyzed to identify resistance‑associated markers using a deep label‑free quantification proteomic analysis. There were >3,000 exosomal proteins identified of which, 35 were found to be differentially expressed. From this, a total of 3, namely the membrane proteins, interferon‑induced transmembrane protein 3, CD146 and CD36, were markedly upregulated in the exosomes derived from the K562IR cells, and exhibited surface localization. The upregulation of these proteins was verified in the K562IR exosomes, and also in the K562IR cells. Using flow cytometric analysis, it was possible to further demonstrate the potential of CD146 as a cell surface marker associated with imatinib resistance in K562 cells. Taken together, these results suggested that exosomes and their respective candidate surface proteins could be potential diagnostic markers of TKI drug resistance in CML therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
International journal of oncology - 58(2021), 2 vom: 22. Feb., Seite 238-250 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hrdinova, Tereza [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.10.2021 Date Revised 11.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3892/ijo.2020.5163 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320538311 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320538311 | ||
| 003 | DE-627 | ||
| 005 | 20231225173808.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3892/ijo.2020.5163 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1068.xml |
| 035 | |a (DE-627)NLM320538311 | ||
| 035 | |a (NLM)33491750 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hrdinova, Tereza |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Exosomes released by imatinib‑resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib‑sensitive cells in the presence of imatinib |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.10.2021 | ||
| 500 | |a Date Revised 11.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Chronic myeloid leukemia (CML) is a malignant hematopoietic disorder distinguished by the presence of a BCR‑ABL1 fused oncogene with constitutive kinase activity. Targeted CML therapy by specific tyrosine kinase inhibitors (TKIs) leads to a marked improvement in the survival of the patients and their quality of life. However, the development of resistance to TKIs remains a critical issue for a subset of patients. The most common cause of resistance are numerous point mutations in the BCR‑ABL1 gene, followed by less common mutations and multiple mutation-independent mechanisms. Recently, exosomes, which are extracellular vesicles excreted from normal and tumor cells, have been associated with drug resistance and cancer progression. The aim of the present study was to characterize the exosomes released by imatinib‑resistant K562 (K562IR) cells. The K562IR‑derived exosomes were internalized by imatinib‑sensitive K562 cells, which thereby increased their survival in the presence of 2 µM imatinib. The exosomal cargo was subsequently analyzed to identify resistance‑associated markers using a deep label‑free quantification proteomic analysis. There were >3,000 exosomal proteins identified of which, 35 were found to be differentially expressed. From this, a total of 3, namely the membrane proteins, interferon‑induced transmembrane protein 3, CD146 and CD36, were markedly upregulated in the exosomes derived from the K562IR cells, and exhibited surface localization. The upregulation of these proteins was verified in the K562IR exosomes, and also in the K562IR cells. Using flow cytometric analysis, it was possible to further demonstrate the potential of CD146 as a cell surface marker associated with imatinib resistance in K562 cells. Taken together, these results suggested that exosomes and their respective candidate surface proteins could be potential diagnostic markers of TKI drug resistance in CML therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a chronic myeloid leukemia | |
| 650 | 4 | |a imatinib mesylate | |
| 650 | 4 | |a drug resistance | |
| 650 | 4 | |a proteomics | |
| 650 | 4 | |a exosome | |
| 650 | 4 | |a tyrosine kinase inhibitor | |
| 650 | 4 | |a surface marker | |
| 650 | 7 | |a BCR-ABL1 fusion protein, human |2 NLM | |
| 650 | 7 | |a CD146 Antigen |2 NLM | |
| 650 | 7 | |a CD36 Antigens |2 NLM | |
| 650 | 7 | |a IFITM3 protein, human |2 NLM | |
| 650 | 7 | |a Membrane Proteins |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a RNA-Binding Proteins |2 NLM | |
| 650 | 7 | |a Imatinib Mesylate |2 NLM | |
| 650 | 7 | |a 8A1O1M485B |2 NLM | |
| 650 | 7 | |a Fusion Proteins, bcr-abl |2 NLM | |
| 650 | 7 | |a EC 2.7.10.2 |2 NLM | |
| 700 | 1 | |a Toman, Ondrej |e verfasserin |4 aut | |
| 700 | 1 | |a Dresler, Jiri |e verfasserin |4 aut | |
| 700 | 1 | |a Klimentova, Jana |e verfasserin |4 aut | |
| 700 | 1 | |a Salovska, Barbora |e verfasserin |4 aut | |
| 700 | 1 | |a Pajer, Petr |e verfasserin |4 aut | |
| 700 | 1 | |a Bartos, Oldrich |e verfasserin |4 aut | |
| 700 | 1 | |a Polivkova, Vaclava |e verfasserin |4 aut | |
| 700 | 1 | |a Linhartova, Jana |e verfasserin |4 aut | |
| 700 | 1 | |a Machova Polakova, Katerina |e verfasserin |4 aut | |
| 700 | 1 | |a Kabickova, Hana |e verfasserin |4 aut | |
| 700 | 1 | |a Brodska, Barbora |e verfasserin |4 aut | |
| 700 | 1 | |a Krijt, Matyas |e verfasserin |4 aut | |
| 700 | 1 | |a Zivny, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Vyoral, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Petrak, Jiri |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of oncology |d 1992 |g 58(2021), 2 vom: 22. Feb., Seite 238-250 |w (DE-627)NLM092583830 |x 1791-2423 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2021 |g number:2 |g day:22 |g month:02 |g pages:238-250 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3892/ijo.2020.5163 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2021 |e 2 |b 22 |c 02 |h 238-250 | ||